𝔖 Bobbio Scriptorium

✦ LIBER ✦

Population pharmacokinetics of tasocitinib (CP-690,550) in patients with moderate to severe plaque psoriasis

Book ID: 116587708
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 42 KB
Volume: 64
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2010.09.665

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PSS17 THE EFFECT OF ORAL CP-690,550 ON P

PSS17 THE EFFECT OF ORAL CP-690,550 ON PRURITUS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

✍ C.M. Mamolo; A.G. Bushmakin; J.C. Cappelleri; M. Stewart 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Tasocitinib (CP-690,550), an oral Janus

Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, significantly improves the symptoms of moderate to severe psoriasis with early onset of efficacy

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB

An evaluation of the effect of tasocitin

An evaluation of the effect of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, on pruritus in patients with plaque psoriasis

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Tasocitinib (CP-690,550), an oral Janus

Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, consistently improves the clinical signs of moderate to severe psoriasis in different body regions

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A comparison of the classic versus the l

A comparison of the classic versus the linear-scaling method calculations of the psoriasis area and severity index as evaluation of plaque psoriasis in patients treated with tasocitinib (CP-690,550)

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

The itch severity item: Mediation modeli

The itch severity item: Mediation modeling and measurement characteristics from a phase IIb trial of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, in patients with plaque psoriasis

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB